AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of alzheimer’s disease

Current Neuropharmacology

Volumn 14, Issue 4, 2016, Pages 364-375

  Wang, Yu ^a   Wang, Hao ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer s disease; Multi target directed ligand

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 2,5 BIS(DIAMINO) 1,4 BENZOQUINONE DERIVATIVE; 7 [(CHLOROBENZYL) OXY] 3,4 DIMETHYLCOUMARIN; AMYLOID PRECURSOR PROTEIN; BENZOFURAN DERIVATIVE; BENZOQUINONE DERIVATIVE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DONEPEZIL; EBSELEN; GALANTAMINE; HUPERZINE A; INDANONE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEPTAZINOL; MONOAMINE OXIDASE A INHIBITOR; PIPERAZINE DERIVATIVE; PMS 1339; PMS 777; RASAGILINE; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; SILIBININ; TACRINE DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; CHELATING AGENT; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYMATIC ASSAY; ENZYME ACTIVE SITE; HUMAN; MOLECULAR DOCKING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN INTERACTION; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; TRADITIONAL MEDICINE; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BINDING SITES; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; HUMANS; LIGANDS; MONOAMINE OXIDASE INHIBITORS; OXIDATIVE STRESS; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84964300328     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X14666160119094820     Document Type: Article

References (89)

1. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell, 2012, 148 (6), 1204-22. http://dx.doi.org/10.1016/j.cell.2012.02.040
2. Amanatkar, H. R.; Grossberg, G. T. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions. Expert Rev. Neurother., 2014, 14 (10), 1119-1125. http://dx.doi.org/10.1586/14737175.2014.955852
3. Tracey, I.; Flower, R. The warrior in the machine: neuroscience goes to war. Nat. Rev. Neurosci., 2014, 15 (12), 825-34. http://dx.doi.org/10.1038/nrn3835
4. Contestabile, A. The history of the cholinergic hypothesis. Behav. Brain Res., 2011, 221 (2), 334-40. http://dx.doi.org/10.1016/j.bbr.2009.12.044
5. Qiu, Y.; Wu, X. J.; Chen, H. Z. Simultaneous changes in secretory amyloid precursor protein and beta-amyloid peptide release from rat hippocampus by activation of muscarinic receptors. Neurosci.Lett., 2003, 352 (1), 41-4. http://dx.doi.org/10.1016/j.neulet.2003.08.022
6. Zhu, X.; Zhou, W.; Cui, Y.; Zhu, L.; Li, J.; Xia, Z.; Shao, B.; Wang, H.; Chen, H. Muscarinic activation attenuates abnormal processing of beta-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells. Biochem. Biophys. Res. Commun., 2009, 384 (1), 110-3. http://dx.doi.org/10.1016/j.bbrc.2009.04.080
7. Zhou, W.; Zhu, X.; Zhu, L.; Cui, Y. Y.; Wang, H.; Qi, H.; Ren, Q. S.; Chen, H. Z. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons. Cell. Mol. Neurobiol., 2008, 28 (2), 263-75. http://dx.doi.org/10.1007/s10571-007-9251-0
8. Tan, P. P.; Yuan, H. H.; Zhu, X.; Cui, Y. Y.; Li, H.; Feng, X. M.; Qiu, Y.; Chen, H. Z.; Zhou, W. Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models. CNS Neurosci. Therap., 2014, 20 (3), 227-36. http://dx.doi.org/10.1111/cns.12187
9. Wang, H.; Lu, Y.; Chen, H. Z. Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice. Neurosci. Lett., 2003, 344 (3), 173-6. http://dx.doi.org/10.1016/S0304-3940(03)00444-0
10. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U. S. A., 1993, 90 (19), 9031-5. http://dx.doi.org/10.1073/pnas.90.19.9031
11. Bachovchin, D. A.; Cravatt, B. F. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat. Rev. Drug Discov., 2012, 11 (1), 52-68. http://dx.doi.org/10.1038/nrd3620
12. Paoletti, P.; Bellone, C.; Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci., 2013, 14 (6), 383-400. http://dx.doi.org/10.1038/nrn3504
13. Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem., 2012, 55 (22), 10282-6. http://dx.doi.org/10.1021/jm300871x
14. Greenfield, S. Discovering and targeting the basic mechanism of neurodegeneration: the role of peptides from the C-terminus of acetylcholinesterase: non-hydrolytic effects of ache: the actions of peptides derived from the C-terminal and their relevance to neurodegeneration. Chemico-Biol. Interact., 2013, 203 (3), 543-6. http://dx.doi.org/10.1016/j.cbi.2013.03.015
15. Zimmermann, M. Neuronal AChE splice variants and their nonhydrolytic functions: redefining a target of AChE inhibitors? Br. J. Pharmacol., 2013, 170 (5), 953-967. http://dx.doi.org/10.1111/bph.12359
16. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-betapeptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16 (4), 881-91. http://dx.doi.org/10.1016/S0896-6273(00)80108-7
17. Koch, M. W.; Korngut, L.; Patry, D. G.; Agha-Khani, Y.; White, C.; Sarna, J. R.; Yeung, M.; Yong, V. W.; Heng, D. Y.; Cutter, G.; Metz, L. The promise of futility trials in neurological diseases. Nat. Rev. Neurol., 2015, 11 (5), 300-305. http://dx.doi.org/10.1038/nrneurol.2015.34
18. Xie, Q.; Wang, H.; Xia, Z.; Lu, M.; Zhang, W.; Wang, X.; Fu, W.; Tang, Y.; Sheng, W.; Li, W.; Zhou, W.; Zhu, X.; Qiu, Z.; Chen, H. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J. Med. Chem., 2008, 51 (7), 2027-36. http://dx.doi.org/10.1021/jm070154q
19. Hou, L. N.; Xu, J. R.; Zhao, Q. N.; Gao, X. L.; Cui, Y. Y.; Xu, J.; Wang, H.; Chen, H. Z. A new motif in the N-terminal of acetylcholinesterase triggers amyloid-beta aggregation and deposition. CNS Neurosci. Ther., 2014, 20 (1), 59-66. http://dx.doi.org/10.1111/cns.12161
20. Cottingham, M. G.; Hollinshead, M. S.; Vaux, D. J. T. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry-Us, 2002, 41 (46), 13539-13547.
21. Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci., 2015, 18 (6), 794-9. http://dx.doi.org/10.1038/nn.4017
22. Benilova, I.; Karran, E.; De Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci., 2012, 15 (3), 349-57. http://dx.doi.org/10.1038/nn.3028
23. Heppner, F. L.; Ransohoff, R. M.; Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci., 2015, 16 (6), 358-72. http://dx.doi.org/10.1038/nrn3880
24. Ryan, S. D.; Whitehead, S. N.; Swayne, L. A.; Moffat, T. C.; Hou, W.; Ethier, M.; Bourgeois, A. J.; Rashidian, J.; Blanchard, A. P.; Fraser, P. E.; Park, D. S.; Figeys, D.; Bennett, S. A. Amyloidbeta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc. Natl. Acad. Sci. U. S. A., 2009, 106 (49), 20936-41. http://dx.doi.org/10.1073/pnas.0905654106
25. Bate, C.; Salmona, M.; Williams, A. The role of platelet activating factor in prion and amyloid-beta neurotoxicity. Neuroreport, 2004, 15 (3), 509-13. http://dx.doi.org/10.1097/00001756-200403010-00025
26. Bate, C.; Kempster, S.; Williams, A. Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microgliamediated death. Neuropharmacology, 2006, 51 (2), 173-81. http://dx.doi.org/10.1016/j.neuropharm.2006.02.015
27. Trillo, L.; Das, D.; Hsieh, W.; Medina, B.; Moghadam, S.; Lin, B.; Dang, V.; Sanchez, M. M.; De Miguel, Z.; Ashford, J. W.; Salehi, A. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci. Biobehav. Rev., 2013, 37 (8), 1363-79. http://dx.doi.org/10.1016/j.neubiorev.2013.05.008
28. Parameshwaran, K.; Dhanasekaran, M.; Suppiramaniam, V. Amyloid beta peptides and glutamatergic synaptic dysregulation. Exper. Neurol., 2008, 210 (1), 7-13. http://dx.doi.org/10.1016/j.expneurol.2007.10.008
29. Leon, R.; Garcia, A. G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev., 2013, 33 (1), 139-89. http://dx.doi.org/10.1002/med.20248
30. Dias, K. S.; Viegas, C., Jr. Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer's Disease. Curr. Neuropharmacol., 2014, 12 (3), 239-55. http://dx.doi.org/10.2174/1570159X1203140511153200
31. Agis-Torres, A.; Solhuber, M.; Fernandez, M.; Sanchez-Montero, J. M. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. Curr. Neuropharmacol., 2014, 12 (1), 2-36. http://dx.doi.org/10.2174/1570159X113116660047
32. Rochais, C.; Lecoutey, C.; Gaven, F.; Giannoni, P.; Hamidouche, K.; Hedou, D.; Dubost, E.; Genest, D.; Yahiaoui, S.; Freret, T.; Bouet, V.; Dauphin, F.; Sopkova de Oliveira Santos, J.; Ballandonne, C.; Corvaisier, S.; Malzert-Freon, A.; Legay, R.; Boulouard, M.; Claeysen, S.; Dallemagne, P. Novel multitargetdirected ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem., 2015, 58 (7), 3172-87. http://dx.doi.org/10.1021/acs.jmedchem.5b00115
33. Xiong, G.; Doraiswamy, P. M. Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics, 2005, 60 (6), 22-6.
34. Dantoine, T.; Auriacombe, S.; Sarazin, M.; Becker, H.; Pere, J. J.; Bourdeix, I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Intl. J. Clin. Practice, 2006, 60 (1), 110-8. http://dx.doi.org/10.1111/j.1368-5031.2005.00769.x
35. Klatte, E. T.; Scharre, D. W.; Nagaraja, H. N.; Davis, R. A.; Beversdorf, D. Q. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2003, 17 (2), 113-6.
36. Weycker, D.; Taneja, C.; Edelsberg, J.; Erder, M. H.; Schmitt, F. A.; Setyawan, J.; Oster, G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receivingdonepezil. Curr. Med. Res. Opin., 2007, 23 (5), 1187-97. http://dx.doi.org/10.1185/030079907X188071
37. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem., 2006, 49 (16), 4961-70. http://dx.doi.org/10.1021/jm0603015
38. Gemma, S.; Gabellieri, E.; Huleatt, P.; Fattorusso, C.; Borriello, M.; Catalanotti, B.; Butini, S.; De Angelis, M.; Novellino, E.; Nacci, V.; Belinskaya, T.; Saxena, A.; Campiani, G. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J. Med. Chem., 2006, 49 (11), 3421-5. http://dx.doi.org/10.1021/jm060257t
39. Munoz-Ruiz, P.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millan, M.; Valenzuela, R.; Usan, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Medina, M.; Martinez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem., 2005, 48 (23), 7223-33. http://dx.doi.org/10.1021/jm0503289
40. Kwon, Y. E.; Park, J. Y.; No, K. T.; Shin, J. H.; Lee, S. K.; Eun, J. S.; Yang, J. H.; Shin, T. Y.; Kim, D. K.; Chae, B. S.; Leem, J. Y.; Kim, K. H. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorg. Med. Chem., 2007, 15 (20), 6596-607. http://dx.doi.org/10.1016/j.bmc.2007.07.003
41. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2- chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem., 2003, 46 (12), 2279-82. http://dx.doi.org/10.1021/jm0340602
42. Guo, T.; Hobbs, D. W. Development of BACE1 inhibitors for Alzheimer's disease. Curr. Med. Chem., 2006, 13 (15), 1811-29. http://dx.doi.org/10.2174/092986706777452489
43. Tarozzi, A.; Bartolini, M.; Piazzi, L.; Valgimigli, L.; Amorati, R.; Bolondi, C.; Djemil, A.; Mancini, F.; Andrisano, V.; Rampa, A. From the dual function lead AP2238 to AP2469, a multi-targetdirected ligand for the treatment of Alzheimer's disease. Pharmacol. Res. Perspect., 2014, 2 (2), e00023. http://dx.doi.org/10.1002/prp2.23
44. Shao, B. Y.; Xia, Z.; Xie, Q.; Ge, X. X.; Zhang, W. W.; Sun, J.; Jiang, P.; Wang, H.; Le, W. D.; Qiu, Z. B.; Lu, Y.; Chen, H. Z. Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice. CNS Neurosci. Ther., 2014, 20 (2), 165-71. http://dx.doi.org/10.1111/cns.12183
45. Lecoutey, C.; Hedoua, D.; Freret, T.; Giannoni, P.; Gaven, F.; Since, M.; Bouet, V.; Ballandonne, C.; Corvaisier, S.; Freon, A. M.; Mignani, S.; Cresteil, T.; Boulouard, M.; Claeysen, S.; Rochais, C.; Dallemagne, P. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Natl. Acad. Sci. U.S.A., 2014, 111 (36), E3825-E3830. http://dx.doi.org/10.1073/pnas.1410315111
46. Le Texier, L.; Favre, E.; Redeuilh, C.; Blavet, N.; Bellahsene, T.; Dive, G.; Pirotzky, E.; Godfroid, J. J. Structure-activity relationships in platelet-activating factor (PAF).7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity. J. Lipid Mediat. Cell Signal., 1996, 13 (3), 189-205. http://dx.doi.org/10.1016/0929-7855(95)00046-1
47. Le Texier, L.; Favre, E.; Ronzani, N.; Massicot, F.; Blavet, N.; Pirotzky, E.; Godfroid, J. J. Structure-activity relationships in platelet-activating factor (PAF).8. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors: antiacetylcholinesterase activity and comparative SAR. J. Lipid Mediat. Cell Signal., 1996, 13 (3), 207-22. http://dx.doi.org/10.1016/0929-7855(95)00053-4
48. Li, J.; Huang, H.; Miezan Ezoulin, J. M.; Gao, X. L.; Massicot, F.; Dong, C. Z.; Heymans, F.; Chen, H. Z. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Intl. J. Neuropsychopharmacol./Oficial Sci. J Collegium Internationale Neuropsychopharmacologicum (CINP), 2007, 10 (1), 21-9.
49. Ezoulin, M. J.; Dong, C. Z.; Liu, Z.; Li, J.; Chen, H. Z.; Heymans, F.; Lelievre, L.; Ombetta, J. E.; Massicot, F. Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. Toxicol. In Vitro, 2006, 20 (6), 824-31. http://dx.doi.org/10.1016/j.tiv.2006.01.002
50. Ezoulin, M. J.; Li, J.; Wu, G.; Dong, C. Z.; Ombetta, J. E.; Chen, H. Z.; Massicot, F.; Heymans, F. Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neurosci. Lett., 2005, 389 (2), 61-5. http://dx.doi.org/10.1016/j.neulet.2005.07.026
51. Ezoulin, M. J.; Liu, Z.; Dutertre-Catella, H.; Wu, G.; Dong, C. Z.; Heymans, F.; Ombetta, J. E.; Rat, P.; Massicot, F. A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Intl. Immunopharmacol., 2007, 7 (13), 1685-94. http://dx.doi.org/10.1016/j.intimp.2007.08.023
52. Li, J.; Hu, J.; Shao, B.; Zhou, W.; Cui, Y.; Dong, C.; Ezoulin, J. M.; Zhu, X.; Ding, W.; Heymans, F.; Chen, H. Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. Cell. Mol. Neurobiol., 2009, 29 (4), 589-95. http://dx.doi.org/10.1007/s10571-009-9351-0
53. Li, J.; Shao, B.; Zhu, L.; Cui, Y.; Dong, C.; Miezan Ezoulin, J. M.; Gao, X.; Ren, Q.; Heymans, F.; Chen, H. PMS777, a bisinteracting ligand for PAF receptor antagonism and AChE inhibition, attenuates PAF-induced neurocytotoxicity in SH-SY5Y cells. Cell. Mol. Neurobiol., 2008, 28 (1), 125-36. http://dx.doi.org/10.1007/s10571-007-9190-9
54. Yang, H. Q.; Sun, Z. K.; Zhao, Y. X.; Pan, J.; Ba, M. W.; Lu, G. Q.; Ding, J. Q.; Chen, H. Z.; Chen, S. D. PMS777, a new cholinesterase inhibitor with anti-platelet activated factor activity, regulates amyloid precursor protein processing in vitro. Neurochem. Res., 2009, 34 (3), 528-35. http://dx.doi.org/10.1007/s11064-008-9816-4
55. Miezan, E.J. M.; Shao, B. Y.; Xia, Z.; Xie, Q.; Li, J.; Cui, Y. Y.; Wang, H.; Dong, C. Z.; Zhao, Y. X.; Massicot, F.; Qiu, Z. B.; Heymans, F.; Chen, H. Z. Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice. Intl. J. Neuropsychopharmacol/Official Sci. J. Collegium Internationale Neuropsychopharmacologicum (CINP), 2009, 12 (10), 1409-19. http://dx.doi.org/10.1021/jm050746d
56. Rodriguez-Franco, M. I.; Fernandez-Bachiller, M. I.; Perez, C.; Hernandez-Ledesma, B.; Bartolome, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem., 2006, 49 (2), 459-62.
57. Pappolla, M. A.; Sos, M.; Omar, R. A.; Bick, R. J.; Hickson-Bick, D. L.; Reiter, R. J.; Efthimiopoulos, S.; Robakis, N. K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci., 1997, 17 (5), 1683-90.
58. Baldwin, W. S.; Barrett, J. C. Melatonin attenuates hydrogen peroxide toxicity in MCF7 cells only at pharmacological concentrations. Biochem. Biophys. Res. Commun., 1998, 250 (3), 602-5. http://dx.doi.org/10.1006/bbrc.1998.9370
59. Lahiri, D. K.; Chen, D. M.; Lahiri, P.; Bondy, S.; Greig, N. H. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann. NY Acad. Sci., 2005, 1056, 430-49. http://dx.doi.org/10.1196/annals.1352.008
60. Cheng, S.; Zheng, W.; Gong, P.; Zhou, Q.; Xie, Q.; Yu, L.; Zhang, P.; Chen, L.; Li, J.; Chen, J.; Chen, H.; Chen, H. (-)-Meptazinolmelatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-beta aggregation with high antioxidant potency for Alzheimer's therapy. Bioorg. Med. Chem., 2015, 23 (13), 3110-8. http://dx.doi.org/10.1016/j.bmc.2015.04.084
61. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem., 2005, 48 (2), 360-3. http://dx.doi.org/10.1021/jm049112h
62. Ono, K.; Hirohata, M.; Yamada, M. Alpha-lipoic acid exhibits antiamyloidogenicity for beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun., 2006, 341 (4), 1046-52. http://dx.doi.org/10.1016/j.bbrc.2006.01.063
63. Jesudason, E. P.; Masilamoni, J. G.; Jesudoss, K. S.; Jayakumar, R. The protective role of DL-alpha-lipoic acid in the oxidative vulnerability triggered by Abeta-amyloid vaccination in mice. Mol. Cell. Biochem., 2005, 270 (1-2), 29-37. http://dx.doi.org/10.1007/s11010-005-3301-z
64. Jesudason, E. P.; Masilamoni, J. G.; Ashok, B. S.; Baben, B.; Arul, V.; Jesudoss, K. S.; Jebaraj, W. C.; Dhandayuthapani, S.; Vignesh, S.; Jayakumar, R. Inhibitory effects of short-term administration of DL-alpha-lipoic acid on oxidative vulnerability induced by Abeta amyloid fibrils (25-35) in mice. Mol. Cell. Biochem., 2008, 311 (1-2), 145-56.
65. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-targetdirected drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem., 2007, 50 (26), 6446-9. http:// dx.doi.org/10.1021/jm701225u
66. Rizzo, S.; Tarozzi, A.; Bartolini, M.; Da Costa, G.; Bisi, A.; Gobbi, S.; Belluti, F.; Ligresti, A.; Allara, M.; Monti, J. P.; Andrisano, V.; Di Marzo, V.; Hrelia, P.; Rampa, A. 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. Eur. J. Med. Chem., 2012, 58, 519-32. http://dx.doi.org/10.1016/j.ejmech.2012.10.045
67. Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.; Luo, H. B.; Huang, L.; Li, X. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J. Med. Chem., 2013, 56 (22), 9089-99. http://dx.doi.org/10.1021/jm401047q
68. Huang, L.; Miao, H.; Sun, Y.; Meng, F.; Li, X. Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease. Eur. J. Med. Chem., 2014, 87, 429-39. http://dx.doi.org/10.1016/j.ejmech.2014.09.081
69. Bruhlmann, C.; Ooms, F.; Carrupt, P. A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44 (19), 3195-8. http://dx.doi.org/10.1021/jm010894d
70. Bautista-Aguilera, O. M.; Samadi, A.; Chioua, M.; Nikolic, K.; Filipic, S.; Agbaba, D.; Soriano, E.; de Andres, L.; Rodriguez- Franco, M. I.; Alcaro, S.; Ramsay, R. R.; Ortuso, F.; Yanez, M.; Marco-Contelles, J. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl) piperidin-4-yl)propoxy)-1H-indol-2- yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J. Med. Chem., 2014, 57 (24), 10455-63. http://dx.doi.org/10.1021/jm501501a
71. Nasica-Labouze, J.; Nguyen, P. H.; Sterpone, F.; Berthoumieu, O.; Buchete, N. V.; Cote, S.; De Simone, A.; Doig, A. J.; Faller, P.; Garcia, A.; Laio, A.; Li, M. S.; Melchionna, S.; Mousseau, N.; Mu, Y.; Paravastu, A.; Pasquali, S.; Rosenman, D. J.; Strodel, B.; Tarus, B.; Viles, J. H.; Zhang, T.; Wang, C.; Derreumaux, P. Amyloid beta Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies. Chem. Rev., 2015, 115 (9), 3518-63. http://dx.doi.org/10.1021/cr500638n
72. Zheng, W.; Li, J.; Qiu, Z.; Xia, Z.; Li, W.; Yu, L.; Chen, H.; Chen, J.; Chen, Y.; Hu, Z.; Zhou, W.; Shao, B.; Cui, Y.; Xie, Q.; Chen, H. Novel bis-(-)-nor-meptazinol derivatives act as dual binding site AChE inhibitors with metal-complexing property. Toxicol. Appl. Pharmacol., 2012, 264 (1), 65-72. http://dx.doi.org/10.1016/j.taap. 2012.07.018
73. Kochi, A.; Eckroat, T. J.; Green, K. D.; Mayhoub, A. S.; Lim, M. H.; Garneau-Tsodikova, S. A novel hybrid of 6-chlorotacrine and metal-amyloid-beta modulator for inhibition of acetylcholinesterase and metal-induced amyloid-beta aggregation. Chem. Sci., 2013, 4 (11), 4137-4145. http://dx.doi.org/10.1039/c3sc51902c
74. Danysz, W.; Parsons, C. G. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br. J. Pharmacol., 2012, 167 (2), 324-52. http://dx. doi.org/10.1111/j.1476-5381.2012.02057.x
75. Rook, Y.; Schmidtke, K. U.; Gaube, F.; Schepmann, D.; Wunsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent betacarbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem., 2010, 53 (9), 3611-7. http://dx.doi.org/10.1021/jm1000024
76. Rosini, M.; Simoni, E.; Minarini, A.; Melchiorre, C. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem. Res., 2014, 39 (10), 1914-23. http://dx.doi.org/10.1007/s11064-014-1250-1
77. Simoni, E.; Daniele, S.; Bottegoni, G.; Pizzirani, D.; Trincavelli, M. L.; Goldoni, L.; Tarozzo, G.; Reggiani, A.; Martini, C.; Piomelli, D.; Melchiorre, C.; Rosini, M.; Cavalli, A. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem., 2012, 55 (22), 9708-21. http://dx.doi.org/10.1021/jm3009458
78. Toda, N.; Kaneko, T.; Kogen, H. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Chem. Pharm. Bull., 2010, 58 (3), 273-87. http://dx.doi.org/10.1248/cpb.58.273
79. Lange, J. H.; Coolen, H. K.; van der Neut, M. A.; Borst, A. J.; Stork, B.; Verveer, P. C.; Kruse, C. G. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism. J. Med. Chem., 2010, 53 (3), 1338-46. http://dx.doi.org/10.1021/jm901614b
80. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodriguez-Franco, M. I.; Lopez, B.; Lopez, M. G.; Garcia, A. G.; Carreiras Mdo, C.; Villarroya, M. Tacripyrines, the first tacrinedihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52 (9), 2724-32. http://dx.doi.org/10.1021/jm801292b
81. Fang, J.; Li, Y.; Liu, R.; Pang, X.; Li, C.; Yang, R.; He, Y.; Lian, W.; Liu, A. L.; Du, G. H. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. J. Chem. Information Modeling, 2015, 55 (1), 149-64. http://dx.doi.org/10.1021/ci500574n
82. Harvey, A. L.; Edrada-Ebel, R.; Quinn, R. J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov., 2015, 14 (2), 111-29. http://dx.doi.org/10.1038/nrd4510
83. Sun, Z. K.; Yang, H. Q.; Chen, S. D. Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's disease. Transl. Neurodegeneration, 2013, 2 (1), 6. http://dx.doi.org/10.1186/2047-9158-2-6
84. Cheung, T. S.; Song, T. H.; Ng, T. B.; Wu, F. H.; Lao, L. X.; Tang, S. C.; Ho, J. C.; Zhang, K. Y.; Sze, S. C. Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer's Disease. Curr. Med. Chem., 2015, 22 (19), 2392-403. http://dx.doi.org/10.2174/0929867322666150520095509
85. Murray, A. P.; Faraoni, M. B.; Castro, M. J.; Alza, N. P.; Cavallaro, V. Natural AChE Inhibitors from Plants and their Contribution to Alzheimer's Disease Therapy. Curr. Neuropharmacol., 2013, 11 (4), 388-413. http://dx.doi.org/10.2174/ 1570159X11311040004
86. Jia, J. Y.; Zhao, Q. H.; Liu, Y.; Gui, Y. Z.; Liu, G. Y.; Zhu, D. Y.; Yu, C.; Hong, Z. Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. Acta Pharmacologica Sinica, 2013, 34 (7), 976-82. http://dx.doi.org/10.1038/aps.2013.7
87. Wei, G.; Xiao, S.; Lu, R.; Liu, C. Simultaneous determination of ZT-1 and its metabolite Huperzine A in plasma by highperformance liquid chromatography with ultraviolet detection. J. Chromatograph. B, Anal. Technol. Biomed. Life Sci., 2006, 830 (1), 120-5. http://dx.doi.org/10.1016/j.jchromb.2005.10.027
88. Bansode, S. B.; Jana, A. K.; Batkulwar, K. B.; Warkad, S. D.; Joshi, R. S.; Sengupta, N.; Kulkarni, M. J. Molecular Investigations of Protriptyline as a Multi-Target Directed Ligand in Alzheimer's Disease. Plos One, 2014, 9 (8). http://dx.doi.org/10.1371/journal.pone.0105196
89. Duan, S.; Guan, X.; Lin, R.; Liu, X.; Yan, Y.; Lin, R.; Zhang, T.; Chen, X.; Huang, J.; Sun, X.; Li, Q.; Fang, S.; Xu, J.; Yao, Z.; Gu, H. Silibinin inhibits acetylcholinesterase activity and amyloid beta peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease. Neurobiol. Aging, 2015, 36 (5), 1792-807. http://dx.doi.org/10.1016/j.neurobiolaging.2015.02.002